Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase Ib Study to Characterise the Antimalarial and Transmission Blocking Activity of a Single Dose of DSM265 or OZ439 in Healthy Subjects With Induced Blood Stage Plasmodium Falciparum or Plasmodium Vivax Infection

Next Previous
Search
Trial Profile

A Phase Ib Study to Characterise the Antimalarial and Transmission Blocking Activity of a Single Dose of DSM265 or OZ439 in Healthy Subjects With Induced Blood Stage Plasmodium Falciparum or Plasmodium Vivax Infection

Status: Discontinued
Phase of Trial: Phase I

Latest Information Update: 06 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Artefenomel (Primary) ; DSM 265 (Primary) ; Artemether/lumefantrine
  • Indications Malaria
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms DSMOZ-2

Most Recent Events

  • 28 Jun 2021 Data from 4 studies (OZ439 monotherapy, DSM265 monotherapy;150 mg, DSM265 monotherapy; 400mg, OZ439/DSM265 combination therapy; 200mg of OZ439 combined with 50 and 100mg of DSM265) were used to evaluate efficacy by using within-host model, published in the Journal of Antimicrobial Chemotherapy
  • 01 Jun 2020 Results (n=8) assessing PK/PD relationship of artefenomel using the P. vivax IBSM model and establishing the minimum dose of artefenomel required to clear P. vivax blood-stage parasitemia, published in the Journal of Infectious Diseases.
  • 13 Jul 2016 Status changed from recruiting to discontinued.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top